RS-8001 is under clinical development by Rena Science and currently in Phase II for Premenstrual Syndrome. According to GlobalData, Phase II drugs for Premenstrual Syndrome have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RS-8001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RS-8001 overview

RS-8001 (pyridoxamine) is under development for the treatment of premenstrual syndrome, premenstrual dysphoric disorder with psychiatric symptoms and autism spectrum disorder. The drug is administered through oral route.

Rena Science overview

Rena Science is a company that develops and markets AI-powered drugs, medical equipment, and medical solutions. The company is headquartered in Chuo, Tokyo, Japan.

For a complete picture of RS-8001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.